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Abstract
Objectives:
To present the Grading of Recommendations Assessment, Development, and Evaluation 
(GRADE) conceptual approach to the assessment of certainty of evidence from modelling 
studies (i.e. model outputs). 
Study Design and Setting:
We performed expert consultations, held an international multi-disciplinary workshop, and 
further elaborated a conceptual approach for assessing the certainty of evidence from models 
within the context of systematic reviews, health technology assessments, and health care 
decisions. We assessed the content validity of the approach obtaining feedback from experts in 
a broad range of modelling and health care disciplines. 
Results:
Workshop participants agreed, that the domains determining the certainty of evidence 
previously identified in the GRADE approach (risk of bias, indirectness, inconsistency, 
imprecision, reporting bias, magnitude of an effect, dose-response relation, and the direction of 
residual confounding) also apply in the context of assessing the certainty of evidence from 
models. The assessment itself will depend on the nature of model inputs and the model itself. 
We distinguished the assessment of the certainty of model outputs from a single model and 
across multiple models. We proposed a framework for selecting the best available evidence 
from models: 1) to develop de novo a model specific to the situation of interest, 2) to identify 
an existing model the outputs of which provide the highest certainty evidence for the situation 
of interest, that could be used either “off the shelf” or after adaptation, and 3) to use outputs 
from multiple models. We also present a summary of preferred terminology to facilitate 
communication among various modelling and health care disciplines.  
Conclusions:
This conceptual GRADE approach provides a framework for using evidence from models in 
health decision making and the assessment of certainty of evidence from a model or models. 
The GRADE Working Group and the modelling community continue developing detailed 
methods and related guidance for the assessment of specific domains determining the certainty 
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What is new
1. General concepts determining the certainty of evidence in the GRADE approach (risk of bias, 
indirectness, inconsistency, imprecision, reporting bias, magnitude of an effect, dose-response 
relation, and the direction of residual confounding) also apply in the context of assessing the 
certainty of evidence from models (model outputs). 
2. Detailed assessment of the certainty of evidence from models differs for the assessment of outputs 
from a single model compared to the assessment of outputs across multiple models. 
3. We propose a framework for selecting the best available evidence from models to inform health 
care decisions: to develop a model de novo, to identify an existing model the outputs of which 
provide the highest certainty evidence, or to use outputs from multiple models.
4. We suggest that the modelling and health care decision making communities collaborate further to 
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Introduction
When direct evidence to inform health decisions is not available or not feasible to measure 
(e.g. long-term effects of interventions or when studies in certain populations are perceived as 
unethical), modelling studies may be used to predict that “evidence” and inform decision-
making.[1, 2] Health decision makers arguably also face many more questions than can be 
reasonably answered with studies that directly measure the outcomes. Formal modelling (as 
opposed to the back-of-the-envelope approaches), therefore, is increasingly being used to 
predict the disease dynamics and burden, the likelihood that an exposure represents a health 
hazard, the impact of interventions on health benefits and harms, or the economic efficiency of 
health interventions, among others [1]. Irrespective of the modelling discipline, decision 
makers need to know the best estimates of the modelled outcomes and how much confidence 
they may have in each estimate.[3] Knowing to what extent one can trust the outputs of a 
model is necessary when using them, frequently together with other information, to support 
health decisions [4]. 
Although a number of guidance documents on how to assess the trustworthiness of estimates 
obtained from different models in several health fields have been previously published [5-16], 
they are limited by combining aspects of methodological rigor together with completeness of 
reporting, and by making no clear distinction among various components affecting the 
trustworthiness of model outputs. Uncertainty about the outcomes estimated through 
modelling may result from the uncertainty about model inputs and from the uncertainty about 
a model itself. Thus, modellers and those using results from models should assess the 
credibility of both.[4] Authors have attempted to develop tools to assess model credibility, but 
many addressed only selected aspects, such as statistical reproducibility of data, the quality of 
reporting[17], or a combination of reporting with aspects of good modelling practices[7, 18-21]. 
Many tools also do not provide sufficiently detailed guidance on how to operationalize 
individual domains or criteria. There is therefore a need for further development of such tools 
in specific disciplines and their validation. Sufficiently detailed guidance for making and 
reporting these assessments is also necessary. 
Models predict outcomes based on model inputs – previous observations, knowledge and 
assumptions about the situation being modelled. Thus, when developing new models or 
assessing whether or not an existing model has been optimally developed, one should specify a 
priori what are the most appropriate and relevant data sources to inform different parameters 
required for the model. These may be either single studies that provide the most direct 
information for the situation being modelled or a systematic review of multiple studies that 
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the risk of bias, directness and consistency of input data, precision of these estimates, and 
other domains specified in the Grading of Recommendations Assessment, Development, and 
Evaluation (GRADE) approach.[22-28]
Various disciplines in health care and related areas that use modelling face similar challenges 
when assessing the evidence generated using models and may benefit from shared solutions. 
We present examples of selected models used in health-related disciplines in Table 1. Building 
on the existing GRADE approach, we aim to refine and expand guidance how to assess the 
certainty of model outputs. We formed a GRADE project group, comprised of individuals with 
expertise in developing models and using model results in health-related disciplines, to create a 
unified framework for assessing the certainty of model outputs to be used in the context of 
systematic reviews [29], health technology assessments, health care guidelines, and other 
health decision-making. In this article, we outline the proposed conceptual approach and clarify 
key terminology (Table 2). The main target audience for this article includes researchers who 
develop models and those who use models to inform health care-related decisions.
What we mean by a model
Authors have used the term model to describe a variety of different concepts [2] and suggested 
several broader or narrower definitions [6, 30], so even modellers in the relatively narrow 
context of health sciences can differ in their views about what constitutes a model. Models vary 
in their structure and degree of complexity. A very simple model might be an equation 
estimating a variable not directly measured, such as the absolute effect of an intervention 
estimated as the product of the intervention’s relative effect and the assumed baseline risk in a 
defined population (risk difference equals relative risk reduction multiplied by an assumed 
baseline risk). On the other end of the spectrum there are elaborate mathematical models, 
such as system dynamics models (e.g. infectious disease transmission), which may contain 
dozens of sophisticated equations that require considerable computing power to solve.
By their nature, such models only resemble the phenomena being modelled – i.e. specific parts 
of the world that are interesting in the context of a particular decision – with necessary 
approximations and simplifications, and to the extent that one actually knows and understands 
the underlying mechanisms.[1] Given the complexity of the world, decision-makers often rely 
on some sort of a model to answer health-related questions. 
In this article, we focus on quantitative mathematical models defined as “mathematical 
framework representing variables and their interrelationships to describe observed phenomena 
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These may be models of systems representing causal mechanisms (aka mechanistic models), 
models predicting outcomes from input data (aka empirical models), and models combining 
mechanistic with empirical approaches (aka hybrid models). We do not consider here statistical 
models used to estimate the associations between measured variables (e.g. proportional 
hazards models or models used for meta-analysis).
The GRADE approach
The GRADE working group was established in the year 2000 and continues as a community of 
people with the aim to create a systematic, and transparent framework for assessing and 
communicating the certainty of the available evidence used in making decisions in healthcare 
and health-related disciplines.[31] The GRADE Working Group now includes over 600 active 
members from 40 countries and serves as a think tank for advancing evidence-based decision-
making in multiple health-related disciplines (www.gradeworkinggroup.org). GRADE is widely 
used internationally by over 100 organizations to address topics related to clinical medicine, 
public health, coverage decisions, health policy, and environmental health. 
The GRADE framework uses concepts that are familiar to health scientists, grouping specific 
items for evaluating the certainty of evidence in conceptually coherent domains. Specific 
approaches to evaluate the concepts may differ depending on the nature of the body of 
evidence (Table 2). GRADE domains include concepts such as risk of bias[28], directness of 
information [24], precision of an estimate[23], consistency of estimates across studies[25], risk 
of bias related to selective reporting[26], strength of the association, presence of a dose-
response gradient, and the presence of plausible residual confounding that can increase 
confidence in estimated effects[27]. The general GRADE approach is applicable irrespective of 
health discipline. It has been applied to rating the certainty of evidence for management 
interventions, health care related tests and strategies [32, 33], prognostic information[34], 
evidence from animal studies[35], use of resources and cost-effectiveness evaluations[36], and 
values and preferences[37, 38]. While the GRADE Working Group has begun to address 
certainty of modelled evidence in the context of test-treatment strategies[39], health care 
resource use and costs[36], and environmental health[40], more detailed guidance is needed 
for complex models such as those used in infectious diseases, health economics, public health, 
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On May 15 and 16, 2017, health scientists participated in a GRADE modelling project group 
workshop in Hamilton, Ontario, Canada, to initiate a collaboration in developing common 
principles for the application of the GRADE assessment of certainty of evidence to modelled 
outputs. The National Toxicology Program of the Department of Health and Human Services in 
the USA and the MacGRADE Center in the Department of Health Research Methods, Evidence, 
and Impact at McMaster University sponsored the workshop which was co-organized by 
MacGRADE Center and ICF International. 
Workshop participants were selected to ensure a broad representation of all modelling related 
fields (Appendix). Participants had expertise in modelling in the context of clinical practice 
guidelines, public health, environmental health, dose-response modelling, physiologically based 
pharmacokinetic (PBPK) modelling, environmental chemistry, physical/chemical property 
prediction, evidence integration, infectious disease, computational toxicology, exposure 
modelling, prognostic modelling, diagnostic modelling, cost effectiveness modelling, 
biostatistics, and health ethics.
Leading up to the workshop, we held three webinars to introduce participants to the GRADE 
approach. Several workshop participants (VM, KT, JB, AR, JW, JLB, HJS) collected and 
summarized findings from literature and the survey of experts as background material that 
provided a starting point for discussion. The materials included collected terminology 
representing common concepts across multiple disciplines that relate to evaluating modelled 
evidence, and a draft framework for evaluating modelled evidence. Participants addressed 
specific tasks in small groups and large group discussion sessions and agreed on key principles 
both during the workshop and through written documents. 
Results
Terminology
Workshop participants agreed on the importance of clarifying terminology to facilitate 
communication among modellers, researchers, and users of model outputs from different 
disciplines. Modelling approaches evolved somewhat independently, resulting in different 
terms being used to describe the same or very similar concepts or the same term being used to 
describe different concepts. For instance, the concept of the extent to which one can 
extrapolate from the available data to the context of interest has been referred to as 

























































Brozek, J et a. GRADE approach to modelled data • MANUSCRIPT
Page 10 of 30
standardized terminology leads to confusion and hinders effective communication and 
collaboration among modellers and users of models.
Overcoming these obstacles would require clarifying the definitions of concepts and agreeing 
on terminology across disciplines. Realizing that this involves changing established customary 
use of terms in several disciplines, workshop participants suggested accepting the use of 
alternative terminology while always being clear about the preferred terms to be used and the 
underlying concept that it refers to (Table 2). Experts attending a World Health Organization's 
consultation have very recently suggested a more extensive set of terms [41]. To facilitate 
future communication, participants of this workshop intend to further collaborate to build a 
comprehensive glossary of terminology related to modelling.
Outline of an approach to using model outputs for decision making
Workshop participants suggested an approach to incorporate model outputs in health-related 
decision making (Figure 1). In this article we only describe the general outline of the suggested 
approach – in subsequent articles we aim to discuss the details of the approach and provide 
more specific guidance how to apply it in different disciplines and contexts. 
Researchers should start by designing a conceptual ideal target model that would best 
represent the actual phenomenon they are considering [13]. This target model would either 
guide the development of a new model or serve as a reference against which existing models 
could be compared. The ideal target model should reflect: 1) the relevant population (e.g., 
patients receiving some diagnostic procedure or exposed to some hazardous substance), 2) the 
exposures or health interventions being considered, 3) the outcomes of interest in that context, 
and 4) their relationships. [42]. Designing a priori a conceptual ideal target model will also 
reduce the risk of intentional or unintentional development of data-driven model, in which 
inputs and structure would be determined by what is feasible to develop given the available 
data and knowledge.
Participants identified 3 options in which users may incorporate model outputs in health 
decision-making (Figure 1):
1. Develop a model de novo designed specifically to answer the very question at hand. 
Workshop participants agreed that in an ideal situation such an approach would almost 
always be the most appropriate for addressing the current problem of interest. Following 
this approach, however, requires suitable skills, ample resources, and time being available. 

























































Brozek, J et a. GRADE approach to modelled data • MANUSCRIPT
Page 11 of 30
whether or not the new model would have any advantage over already existing models 
previously developed for the same or similar purpose.
2. Search for an existing model describing the same or a very similar problem and use it “off-
the-shelf” or adapt it appropriately in order to answer the current question. In practice 
many researchers initially use this approach because of the above limitations of developing 
a new model. However, it is often not possible to find an existing model that would be 
directly relevant to the problem at hand and/or it is not feasible to adapt an existing model 
when found. Any adaptation of a model requires availability of input data relevant for 
current problem, appropriate expertise and resources, and access to the original model. The 
latter is often not available (e.g. proprietary model or no longer maintained) or the 
structure of the original model is not being transparent enough to allow adaptation (“black-
box”). 
3. Use the results from multiple existing models found in the literature [43]. This approach 
may be useful when a limited knowledge about the phenomenon being modelled makes it 
impossible to decide which of the available models is more relevant, or when many 
alternative models are relevant but use different input parameters. In such situations, one 
may be compelled to rely on the results of several models, because an arbitrary selection of 
the single, seemingly “best” model may provide incorrect estimates of outputs and lead to incorrect 
decisions owing to “model selection bias”.
Identifying existing models that are similar to the ideal target model often requires performing 
a scoping of the literature or a complete systematic review of potentially relevant models – a 
structured process following a standardized set of methods with a goal to identify and assess all 
available models that are accessible, transparently reported, and fulfil the pre-specified 
eligibility criteria based on the conceptual ideal target model. Some prefer the term systematic 
survey that differs from a systematic review in the initial intention to use the results: in 
systematic reviews the initial intention is to combine the results across studies either 
statistically through a meta-analysis or narratively summarizing their results when appropriate, 
whereas in a systematic survey the initial intention is to examine the various ways that an 
intervention or exposure has been modelled, to review the input evidence that has been used, 
and ultimately to identity a single model that fits the conceptual ideal target model the best or 
requires the least adaptation; only when such one model cannot be found, one may need to 
use the results of multiple existing models.
If a systematic search revealed one or more models meeting the eligibility criteria, then 
researchers would assess the certainty of outputs from each model. Depending on this 
assessment, researchers may be able to use the results of a single most direct and lowest risk of 
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existing model that would be sufficiently direct and low risk of bias, then they would ideally 
develop their own model de novo. 
 
Assessing the certainty of outputs from a single model
When researchers develop their own model or when they identify a single model that is 
considered sufficiently direct to the problem at hand, then they should assess the certainty of 
its outputs (i.e. evidence generated from that model). Note, that if a model estimates multiple 
outputs, researchers needs to assess the certainty of each output separately [23-28]. Workshop 
participants agreed that all GRADE domains are applicable to assess the certainty of model 
outputs, but further work is needed to identify examples and develop specific criteria to be 
assessed, which may differ depending on the model being used and/or situation being 
modelled.
Risk of bias in a single model
The risk of bias of model outputs (i.e. model outputs being systematically overestimated or 
underestimated) is determined by the credibility of a model itself and the certainty of evidence 
for each of model inputs.
The credibility of a model, also referred to as the quality of a model (Table 2) is influenced by 
its conceptualization, structure, calibration, validation, and other factors. Determinants of 
model credibility are likely to be specific to a modelling discipline (e.g., health economic models 
have different determinants of their credibility, compared with PBPK models). There are some 
discipline-specific guidelines or checklists developed for the assessment of credibility of a 
model and other factors affecting the certainty of model outputs such as the framework to 
assess adherence to good practice guidelines in decision-analytic modelling [18], the 
questionnaire to assess relevance and credibility of modelling studies [18, 44, 45], good 
research practices for modelling in health technology assessment [5, 6, 8, 9, 12-14], the 
approaches to assessing uncertainty in read-across [46], and the quantitative structure-activity 
relationships [47] in predictive toxicology. Workshop participants agreed that there is a need 
for comprehensive tools developed specifically to assess credibility of various types of models 
in different modelling disciplines.
The certainty of evidence in each of model inputs is another critical determinant of the risk of 
bias in a model. A model has several types of input data – bodies of evidence used to populate 
a model (Table 2). When researchers develop their model de novo, in order to minimize the risk 

























































Brozek, J et a. GRADE approach to modelled data • MANUSCRIPT
Page 13 of 30
sensitive. For instance, in economic models these key parameters may include health effects, 
resource use, utility values, and baseline risks of outcomes. Model inputs should reflect the 
entire body of relevant evidence satisfying clear pre-specified criteria rather than an arbitrarily 
selected evidence that is based on convenience (“any available evidence”) or picked in any 
other non-systematic way (e.g., “first evidence found” – single studies that researchers happen 
to know about or are the first hits in a database search). The appropriate approach will depend 
on the type of data and may require performing a systematic review of evidence on each 
sensitive input variable [48-50]. Some inputs may have a very narrow inclusion criteria and 
therefore evidence from single epidemiological survey or population surveillance may provide 
all relevant data for the population of interest (e.g. baseline population incidence or 
prevalence). 
The certainty of evidence for each input needs to be assessed following the established GRADE 
approach specific to that type of evidence (e.g. estimates of intervention effects or baseline risk 
of outcomes)[22, 32, 34, 37]. Following the logic of the GRADE approach, that the overall 
certainty of evidence cannot be higher than the lowest certainty for any body of evidence that 
is critical for a decision [51], we put forward that the overall rating of certainty of evidence 
across all model inputs should be limited by the lowest certainty rating for any body of 
evidence (input data) to which the model output(s) have been found sensitive. 
Application of this approach requires a priori consideration of likely critical and/or important 
inputs when specifying the conceptual ideal target model and the examination of the results of 
back-end sensitivity analyses. In some cases, the above principle can extend to encompass 
decision uncertainty – the overall rating of certainty across model inputs for a single model 
should be tied to the certainty rating of the lowest rated body of evidence (input data) to which 
the decision is sensitive. For example, the latter extension is applicable when the outputs of a 
model-based economic evaluation include probabilities of an intervention (versus its 
comparator(s)) being cost-effective at a specified willingness-to-pay threshold.
Indirectness in a single model
By directness or relevance, we mean the extent to which model outputs directly represent the 
phenomenon being modelled. To evaluate the relevance of a model, one needs to compare it 
against the conceptual ideal target model. When there are concerns about the directness of the 
model or there is limited understanding of the system being modelled making it difficult to 
assess directness, then one may have lower confidence in model outputs. 
Determining the directness of model outputs includes the assessment to what extent the 
modelled population, the assumed interventions and comparators, the time horizon, the 
analytic perspective, as well as the outcomes being modelled reflect those that are current 
interest. For instance, if the question is about the risk of birth defects in children of mothers 
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evidence if the model assumed short-term exposure, the route of exposure was different, or 
the effects of exposure to a similar but not the same substance were measured.
Assessing indirectness in a single model requires evaluating 2 separate sources of indirectness: 
1. indirectness of model inputs with respect to the model
2. indirectness of model outputs with respect to the decision problem at hand.
This conceptual distinction is important, because each type of indirectness needs to be 
assessed separately, even though co certain extent the latter may be determined by the 
former. Some authors also distinguish the “indirectness of the model structure with respect to 
decision problem at hand”, but we considered this part of risk of bias described above. 
Using an existing model has an inherent limitation, that its inputs might have been direct for 
the decision problem addressed by its developers but are not direct with respect to the 
problem currently at hand. In this context, sensitivity analysis can help to assess to what extent 
model outputs are robust to the changes in input data or assumptions used in model 
development. 
Inconsistency in a single model
Inconsistency refers to the difference in the results among two or more models. In the case of 
using a single model, this type of inconsistency becomes irrelevant. However, a single model 
may yield inconsistent outputs owing to an unexplained variability in the results of individual 
studies informing the best, pooled estimates of input variables. For instance, when developing 
a health economic model, a systematic review may yield several credible, but discrepant, utility 
estimates in the population of interest. If there is no plausible explanation for that difference in 
utility estimates, outputs of a model based on those inputs may also be inconsistent. Again, 
sensitivity analysis may help to make a judgment to what extent such inconsistency of model 
inputs would translate into a meaningful inconsistency in model outputs with respect to the 
decision problem at hand. 
Imprecision in a single model
The overall certainty of model outputs may also be lower when the outputs are estimated 
imprecisely. For quantitative outputs one should examine not only the point estimate (e.g., 
average predicted event) but also the variability of that estimate (e.g., results of the 
probabilistic sensitivity analysis based in the distribution of the input parameters). It is essential 
that a report from a modelling study always includes information about output variability. 
Further guidance on how to assess imprecision in model outputs will need to take into account 
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in environmental health, model inputs are frequently qualitative. Users of such models may 
assess “adequacy” of the data, i.e. the degree of “richness” and quantity of data supporting 
particular outputs of a model.
 
Risk of publication bias in the context of a single model
The risk of publication bias, also known as “reporting bias”, “non-reporting bias”, or “bias owing 
to missing results”, as it is currently called in the Cochrane Handbook [52], is the likelihood that 
relevant models have been constructed but were not published or otherwise made publicly 
available. Risk of publication bias may not be relevant when assessing the certainty of outputs 
of a single model constructed de novo. However, when one intends to reuse an existing model 
but is aware or strongly suspects that similar models had been developed but are not available, 
then one may be inclined to think that their outputs might have systematically differed from 
the model that is available. In such a case, one may have lower confidence in the outputs of the 
identified model if there is no reasonable explanation for the inability to obtain those other 
models. 
Domains that increase the certainty of outputs from a single model
The GRADE approach to rating the certainty of evidence recognized three situations when the 
certainty of evidence can increase: large magnitude of an estimated effect, presence of a dose-
response gradient in an estimated effect, and an opposite direction of plausible residual 
confounding.[27] Workshop participants agreed that presence of a dose-response gradient in 
model outputs may applicable in some modelling disciplines (e.g., environmental health). 
Similarly, whether or not a large magnitude of an effect in model outputs increases the 
certainty of the evidence may depend on the modelling discipline. The effect of an opposite 
direction of a plausible residual confounding seems theoretically also applicable in assessing 
the certainty of model outputs but an actual example of this phenomenon in modelling studies 
has yet to be found. 
Assessing the certainty of outputs across multiple models
Not infrequently, particularly in disciplines relying on mechanistic models, the current 
knowledge about the real system being modelled is very limited precluding the ability to 
determine which of the available existing models generates higher certainty outputs. Therefore, 
it may be necessary to rely on the results across multiple models. Other examples include using 
multiple models when no model was developed for the population directly of interest (e.g. the 

























































Brozek, J et a. GRADE approach to modelled data • MANUSCRIPT
Page 16 of 30
modelling studies that compared different mammography screening intervals [53]) or when 
multiple models of the same situation exist but vary in structure, complexity, and parameter 
choices (e.g. HIV Modelling Consortium compared several different mathematical models 
simulating the same antiretroviral therapy program and found that all models predicted that 
the program has the potential to reduce new HIV infections in the population [54]).  
When researchers choose or are compelled to include outputs from several existing models, 
they should assess the certainty of outputs across all included models. This assessment may be 
more complex than for single models and single bodies of evidence. The feasibility of GRADE’s 
guidance to judge the certainty of evidence lies in the availability of accepted methods for 
assessing most bodies of evidence from experimental to observational studies. However, the 
methods for systematic reviews of modelling studies are less well-established, some stages of 
the process are more complex, the number of highly skilled individuals with experience in such 
systematic reviews is far lower, and there is larger variability in the results [55]. Additionally, 
researchers must be careful to avoid “double counting” the same model as if it were multiple 
models. For instance, the same model (i.e. same structure and assumptions) may have been 
used in several modelling studies, in which investigators relied on different inputs. When facing 
this scenario, researchers may need to decide which of the inputs are the most direct to their 
particular question and include in only this model in the review.  
Risk of bias across multiple models
The assessment of risk of bias across models involves an assessment of the risk of bias in each 
individual model (see above discussion of risk of bias in single model) and subsequently making 
a judgement about the overall risk of bias across all included models. Specific methods for 
operationalizing this integration remain to be developed.
Indirectness across multiple models
As for the risk of bias, researchers need to assess indirectness of outputs initially for each of 
included models and then integrate the judgements across models. Likewise, specific methods 
for operationalizing this integration still remain to be developed. During this assessment 
researchers may find some models too indirect to be informative for their current question and 
decide to exclude them from further consideration. However, the criteria to determine which 
models are too indirect should be developed a priori, before the search for the models is 
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Imprecision across multiple models
The overall certainty of model outputs may also be lower when model outputs are not 
estimated precisely. If researchers attempt a quantitative synthesis of outputs across models, 
they will report the range of estimates and variability of that estimates. When researchers 
choose to perform only a qualitative summary of the results across models, it is desirable that 
they report some estimate of variability in the outputs of individual models and an assessment 
of how severe the variability is (e.g. range of estimated effects).
Inconsistency of outputs across multiple models
The assessment of inconsistency should focus on unexplained differences across model 
outputs. If multiple existing models addressing the same issue produce considerably different 
outputs or reach contrasting conclusions, then careful comparison of the models may lead to a 
deeper understanding of the factors that drive outputs and conclusions. Ideally, the different 
modelling groups that developed relevant models would come together to explore the 
importance of differences in the type and structure of their models, and of the data used as 
model inputs. 
Invariably there will be some differences among the estimates from different models. 
Researchers will need to assess whether or not these differences are important, i.e. whether 
they would lead to different conclusions. If the differences are important but can be explained 
by model structure, model inputs, the certainty of the evidence of the input parameters or 
other relevant reasons, one may present the evidence separately for the relevant subgroups. If 
differences are important, but cannot be clearly explained, the certainty of model outputs may 
be lower. 
Risk of publication bias across multiple models
The assessment is similar to that of the risk of publication bias in the context of a single model.
Domains that increase the certainty of outputs across multiple models
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The goal of the GRADE project group on modelling is to provide concepts and operationalization 
of how to rate the certainty of evidence in model outputs. This article provides an overview of 
the conclusions of the project group. This work is important because there is a growing need 
and availability of modelled information resulting from a steadily increasing knowledge of the 
complexity of the structure and interactions in our environment, and computational power to 
construct and run models. Users of evidence obtained from modelling studies need to know 
how much trust they may have in model outputs. There is a need to improve the methods of 
constructing models and to develop methods for assessing the certainty in model outputs. In 
this article we have attempted to clarify the most important concepts related to developing and 
using model outputs to inform health-related decision-making. Our preliminary work identified 
confusion about terminology, lack of clarity of what is a model, and need for methods to assess 
certainty in model outputs as priorities to be addressed in order to improve the use of evidence 
from modelling studies. 
In some situations, decision-makers might be better off developing a new model specifically 
designed to answer their current question. However, we suggest that it is not always feasible to 
develop a new model or that developing a new model might not be any better than using 
already existing models, when the knowledge of the real life system to be modelled is limited 
precluding the ability to choose one model that would be better than any other. Thus, 
sometimes it may be necessary or more appropriate to use one or multiple existing models 
depending on their availability, credibility, and relevance to the decision-making context. The 
assessment of the certainty of model outputs will be conceptually similar when a new model is 
constructed, or one existing model is used. The main difference between the latter two 
approaches is the availability of information to perform a detailed assessment. That is, 
information for one’s own model may be easily accessible, but information required to assess 
someone else’s model will often be more difficult to obtain. Assessment of the certainty 
evidence across models can build on existing GRADE domains but requires different 
operationalization. 
Adoption of the GRADE approach by modelling disciplines and further development of methods 
to assess the certainty of model outputs may be beneficial for health decision making, since it 
builds on an existing, widely used framework that includes a systematic and transparent 
evaluation process. Systematic approaches improve rigor of research, reducing the risk of error 
and its potential consequences; transparency of the approach increases its trustworthiness. 
There may be additional benefits related to other aspects of the broader GRADE approach, for 
instance a potential to reduce unnecessary complexity and workload in modelling by careful 
consideration of the most direct evidence as model inputs. This may allow, for instance, 
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introduce unnecessary complexity by considering multiple measures of the same outcome 
when focus could be on the most direct outcome measure. 
The GRADE working group will continue developing methods and guidance for using model 
outputs in health-related decision-making. In subsequent articles we will provide more detailed 
guidance about choosing the “best” model when multiple models are found, using multiple 
models, integrating the certainty of evidence from various bodies of evidence with credibility of 
the model and arriving at the overall certainty in model outputs, how to assess the credibility of 
various types of models themselves, and further clarification of terminology. In the future we 
aim to develop and publish the detailed guidance for assessing certainty of evidence from 
models, the specific guidance for the use of modelling across health care-related disciplines 
(e.g. toxicology, environmental health or health economics), validation of the approach, and 
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Table 1. Examples of modelling methods in health-related disciplines (not comprehensive).
Structured model representing health care pathways examining effects of an 
intervention on outcomes of interest.
Types
 Decision tree models
 State transition models 
o Markov cohort simulation
o Individual based microsimulation (first-order Monte Carlo) 
 Discrete event simulation
 Dynamic transmission models




 Estimation of long-term benefits and harms outcomes from complex 
intervention, e.g. minimum unit pricing of alcohol
 Cost effectiveness analysis of 18 FDG PET/CT for the diagnosis of lung cancer
Computational models developed to organize, analyse, simulate, visualize or 
predict toxicological and ecotoxicological effects of chemicals. In some cases, these 
models are used to estimate the toxicity of a substance even before it has been 
synthesized.
Types
 Structural alerts and rule-based models 
 Read-Across
 Dose response and Time response
 Toxicokinetic (TK) and toxicodynamic(TD) 
 Uncertainty factors
 Quantitative structure activity relationship (QSAR)




 Structural alerts for mutagenicity and skin sensitisation
 Read-across for complex endpoints such as chronic toxicity
 Pharmacokinetic (PK) models to calculate concentrations of substances in 
organs, following a variety of exposures QSAR models for carcinogenicity
 TGx-DDI biomarker to detect DNA damage-inducing agents
The EPA defined these models as: ‘A simplification of reality that is constructed to 
gain insights into select attributes of a physical, biological, economic, or social 
system.’ It involves the application of multidisciplinary knowledge to explain, 
explore and predict the Earth´s response to environmental change, and the 
interactions between human activities and natural processes.
Environmental 
models
Classification (based on the CREM guidance document):
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 Natural systems process
 Emission models
 Fate and transport models
 Exposure models
 Human health effects models
 Ecological effects models
 Economic impact models
 Noneconomic impact models
Examples
 Land use regression models
 IH SkinPerm [56]
 ConsExpo [57]
 other exposure models [58]
Other  HopScore: An Electronic Outcomes-Based Emergency Triage System [59]
 Computational general equilibrium (CGE) models [60]
Table 2. Selected commonly used and potentially confusing terms used in the context of 
modelling and the GRADE approach 
Term General definition
Sources of evidence
(may come from in vitro or in vivo experiment or a mathematical model)
Streams of 
evidence
Parallel information about the same outcome that may have been 
obtained using different methods of estimating that outcome. For 
instance, evidence of the increased risk for developing lung cancer in 
humans after an exposure to certain chemical compound may come from 
several streams of evidence: 1) mechanistic evidence – models of 
physiological mechanisms, 2) studies in animals – observations and 
experiments in animals from different phyla, classes, orders, families, 
genera, and species (e.g., bacteria, nematodes, insects, fish, mice, rats), 
and 3) studies in humans. 
Bodies of evidence Information about multiple different aspects around a decision about the 
best course of action. For instance, in order to decide whether or not a 
given diagnostic test should be used in some people, one needs to 
integrate the bodies of evidence about: the accuracy of the test, the 
prevalence of the conditions being suspected, the natural history of these 
conditions, the effects of potential treatments, values and preferences of 
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(may refer to many concepts, thus alternative terms are preferred to reduce confusion)
Certainty of model 
outputs
Alternative terms:
▪ certainty of 
modelled evidence
▪ quality of evidence
▪ quality of model 
output 
▪ strength of 
evidence
▪ confidence in 
model outputs
In the context of health decision-making, the certainty of evidence (term 
preferred over “quality” in order to avoid confusion with the risk of bias in 
an individual study) reflects the extent to which one’s confidence in an 
estimate of an effect is adequate to make a decision or a 
recommendation. Decisions are influenced not only by the best estimates 
of the expected desirable and undesirable consequences but also by one’s 
confidence in these estimates. In the context of evidence syntheses of 
separate bodies of evidence (e.g., systematic reviews), the certainty of 
evidence reflects the extent of confidence that an estimate of effect is 
correct. For instance, the attributable national risk of cardiovascular 
mortality resulting from exposure to air pollution measured in selected 
cities.
The GRADE Working Group published several articles explaining the 
concept in detail.[22-28, 61] Note that the phrase “confidence in an 
estimate of an effect” does not refer to statistical confidence intervals. 
Certainty of evidence is always assessed for the whole body of evidence 
rather than on a single study level (single studies are assessed for risk of 
bias and indirectness).
Certainty of model 
inputs
Alternative term:
▪ quality of model 
inputs
Characteristics of data that are used to develop, train, or run the model, 
e.g., source of input values, their manipulation prior to input into a model, 
quality control, risk of bias in data, etc.
Credibility of a 
model
Alternative terms:
▪ quality of a model
▪ risk of bias in a 
model
▪ validity of a model
To avoid confusion and keep with terminology used by modelling 
community[7] we suggest using the term credibility rather than quality of a 
model. The concept refers to the characteristics of a model itself – its 
design or execution – that affect
the risk that the results may overestimate or underestimate the true 
effect. Various factors influence the overall credibility of a model, such as 
its structure, the analysis and the validation of the assumptions made 
during modelling.
Quality of reporting Refers to how comprehensively and clearly model inputs, a model itself, 
and model outputs have been documented and described such that they 
can be critically evaluated and used for decision-making. Quality of 
reporting and quality of a model are separate concepts: a model with a 
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By directness of a model we mean the extent to which the model 
represents the real-life situation being modelled which is dependent on 
how well the input data and the model structure reflect the scenario of 
interest.
Directness is the term used in the GRADE approach, because each of the 
alternatives has been used usually in a narrower meaning.
* There may be either subtle or fundamental differences among some disciplines in how these 
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